Seawolf Therapeutics launches with $100 million financing and Sanofi deal
On November 16, 2026, Seawolf Therapeutics launched publicly after raising $100 million and signing a Sanofi alliance worth up to $1.2 billion in biobucks. The partnership covers undisclosed treatments for bleeding disorders and other conditions, with Seawolf eligible for royalties, while its TRIDENT platform is designed to deliver redosable DNA medicines through lipid nanoparticles. Seawolf's lead metabolic-disease program has only been tested in animals; the company expects to select a candidate by late 2027 and seek to start human trials by the end of 2028.
Why it matters
The agreement gives Sanofi access to Seawolf's early-stage DNA delivery platform and gives Seawolf financing plus a large potential milestone stream. The lead program remains preclinical, and CEO Elizabeth Alcamo said the company will probably need more capital before human testing.
Key facts
- 1Seawolf's financing included Versant Ventures, Novartis Venture Fund, Eli Lilly, CRISPR Therapeutics and other investors. biospace.com
- 2The Sanofi collaboration covers multiple targets, including bleeding disorders and other undisclosed indications. biospace.com
- 3Seawolf's TRIDENT system is a redosable lipid nanoparticle platform for delivering DNA payloads without viral vectors. globalbankingandfinance.com
- 4The lead program is intended to build muscle and reduce fat, with possible use in obesity, muscle loss and osteoporosis. globalbankingandfinance.com
- 5Sanofi's agreement includes an upfront payment, but its amount was not disclosed. globalbankingandfinance.com
Open questions
- The amount of Sanofi's upfront payment is undisclosed.
- Seawolf has not disclosed detailed information about its lead drug candidate.
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.